Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $260,375.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the sale, the chief executive officer now directly owns 990,392 shares in the company, valued at approximately $20,629,865.36. This represents a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $21.08 on Friday. Enliven Therapeutics, Inc. has a 1-year low of $15.96 and a 1-year high of $30.03. The business’s fifty day moving average price is $21.31 and its two-hundred day moving average price is $23.76. The firm has a market capitalization of $1.03 billion, a PE ratio of -11.09 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC grew its stake in shares of Enliven Therapeutics by 3.2% in the fourth quarter. FMR LLC now owns 6,495,871 shares of the company’s stock worth $146,157,000 after purchasing an additional 199,692 shares in the last quarter. Polar Capital Holdings Plc grew its stake in shares of Enliven Therapeutics by 267.6% in the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock worth $53,768,000 after purchasing an additional 1,739,668 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Enliven Therapeutics by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock worth $44,452,000 after purchasing an additional 55,283 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Enliven Therapeutics by 27.9% in the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock worth $30,001,000 after purchasing an additional 290,153 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its stake in shares of Enliven Therapeutics by 16.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock worth $21,877,000 after purchasing an additional 135,969 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ELVN. BTIG Research began coverage on Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. HC Wainwright increased their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $38.75.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.